/LIMN

LIMN Stock - Liminatus Pharma, Inc. Class A Common Stock

Q: What is the analyst price target for LIMN?

Analyst price target information is not currently available for LIMN.

Q: What is LIMN's market cap?

Market capitalization information is not currently available for LIMN.

Healthcare|Biotechnology|NASDAQ

$0.79-2.46%

$0.02 (-2.46%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.87

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for LIMN

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2021

FY2022

FY2023

FY2024

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.38

52W High$33.66

52W Low$0.61

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021
Revenue	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A
Operating Income	$-2,906,319	$-2,586,211	$-2,709,000	$-2,534,272
Net Income	$-2,904,299	$-1,226,218	$-2,928,000	$4.37M
Net Margin	N/A	N/A	N/A	N/A
EPS	$-0.40	$-0.15	$-0.08	$0.13

Company Overview

Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.

Visit Website

Earnings History & Surprises

LIMN

Beat Rate

Last 0 quarters

Avg Surprise

+0%

EPS vs Estimate

Beats / Misses

0/0

Last 12 quarters

Latest EPS

$-0.07

Q4 2025

EPS Surprise History

Q4 25

No data

Q4 25

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Feb 12, 2026	—	—	—	—
Q4 2025	Nov 13, 2025	—	$-0.07	—	—
Q4 2025	Oct 3, 2025	—	$-0.05	—	—

Frequently Asked Questions about LIMN

What is LIMN's current stock price?

Liminatus Pharma, Inc. Class A Common Stock (LIMN) is currently trading at $0.79 per share. The stock has moved -2.46% today.

What is the analyst price target for LIMN?

No analyst price targets are currently available for this stock.

What sector is Liminatus Pharma, Inc. Class A Common Stock in?

Liminatus Pharma, Inc. Class A Common Stock operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is LIMN's market cap?

Liminatus Pharma, Inc. Class A Common Stock has a market capitalization of $0.02 billion, making it a small-cap company.

Does LIMN pay dividends?

No, Liminatus Pharma, Inc. Class A Common Stock does not currently pay a dividend to shareholders.